Here is an arbitrary list of European issuers which must be scratching their heads about what to do ...
While average numbers are not always useful, it is worth mentioning that out of the 20 HoldCos und...
Medtechs are going nowhere. The post Covid darlings are no longer much in demand.
With much of Sandoz’s upside already captured, betting on Hikma’s (albeit still nascent) growth in its...